CoChat
Sign Up
Cited by 154

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure

Solomon, Scott D., Ostrominski, John W., Wang, Xiaowen, Shah, Sanjiv J., Borlaug, Barry A., Butler, Javed, Davies, Melanie J., Kitzman, Dalane W., Verma, Subodh, Abildstrøm, Steen Z., Nygaard Einfeldt, Mette, Rasmussen, Søren, Abhayaratna, Walter P., Ahmed, Fozia Z., Ben-Gal, Tuvia, Chopra, Vijay, Ito, Hiroshi, Merkely, Bela, Núñez, Julio, Senni, Michele, van der Meer, Peter, Wolf, Dennis, Petrie, Mark C., Kosiborod, Mikhail N.·2024·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2024.08.021
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2024.08.021

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the echocardiographic analysis from the STEP-HFpEF study, effects of semaglutide on paracardiac fat were not reported.

    “In the echocardiographic analysis from the STEP-HFpEF study, effects of semaglutide on paracardiac fat were not reported.11”

    From Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure (2025) · cites this paper as [11]

  • In the STEP-HFpEF study, LV mass reduction was not seen in the semaglutide group over 52 weeks of therapy.

    “In the STEP-HFpEF (Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity) study in a similar patient population to the present study, LV mass reduction was not seen in the semaglutide group over 52 weeks of therapy”

    From Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure (2025) · cites this paper as [11]

  • LA volume was reduced by 6 mL with treatment in the STEP-HFpEF echocardiographic substudy.

    “LA volume was reduced by 6 mL with treatment in the STEP-HFpEF echocardiographic substudy as well”

    From Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure (2025) · cites this paper as [11]

  • Echocardiographically estimated LV filling pressures have been shown to improve with GLP-1 RA in HFpEF, as shown in the STEP-HFpEF echocardiographic substudy.

    “Echocardiographically estimated LV filling pressures have been shown to improve with GLP-1 RA in HFpEF, as shown in the STEP-HFpEF echocardiographic substudy with improved E-wave velocity, early/late mitral inflow velocity ratio, and early mitral inflow velocity/early diastolic mitral annular velocity.11”

    From Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure (2025) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Ammar, 2007, Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community, Circulation, 115, 1563, 10.1161/CIRCULATIONAHA.106.666818 · DOI
  2. Shah, 2014, Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial, Circ Heart Fail, 7, 740, 10.1161/CIRCHEARTFAILURE.114.001583 · DOI
  3. Shah, 2019, Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction, J Am Coll Cardiol, 74, 2858, 10.1016/j.jacc.2019.09.063 · DOI
  4. Lai, 2017, Obesity-related changes in cardiac structure and function among Asian Men and Women, J Am Coll Cardiol, 69, 2876, 10.1016/j.jacc.2017.04.016 · DOI
  5. Litwin, 2020, Longitudinal changes in cardiac structure and function in severe obesity: 11-year follow-up in the Utah Obesity Study, J Am Heart Assoc, 9
  6. Bello, 2016, Association of weight and body composition on cardiac structure and function in the ARIC Study (Atherosclerosis Risk in Communities), Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.115.002978 · DOI
  7. Wong, 2006, Association of subclinical right ventricular dysfunction with obesity, J Am Coll Cardiol, 47, 611, 10.1016/j.jacc.2005.11.015 · DOI · Paper page
  8. Redfield, 2023, Heart failure with preserved ejection fraction: a review, JAMA, 329, 827, 10.1001/jama.2023.2020 · DOI · Paper page
  9. Obokata, 2017, Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction, Circulation, 136, 6, 10.1161/CIRCULATIONAHA.116.026807 · DOI · Paper page
  10. Scandalis, 2023, Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction, JAMA Cardiol, 8, 575, 10.1001/jamacardio.2023.0957 · DOI
  11. Adamson, 2022, Dapagliflozin for heart failure according to body mass index: the DELIVER trial, Eur Heart J, 43, 4406, 10.1093/eurheartj/ehac481 · DOI
  12. Tsujimoto, 2017, Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF, J Am Coll Cardiol, 70, 2739, 10.1016/j.jacc.2017.09.1111 · DOI
  13. Shah, 2024, Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials, Eur Heart J, 45, 3254, 10.1093/eurheartj/ehae322 · DOI · Paper page
  14. Kramer, 2010, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach, J Am Coll Cardiol, 56, 392, 10.1016/j.jacc.2010.05.011 · DOI
  15. McDonagh, 2021, 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 42, 3599, 10.1093/eurheartj/ehab368 · DOI · Paper page
  16. Heidenreich, 2022, 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 79, e263, 10.1016/j.jacc.2021.12.012 · DOI · Paper page
  17. Solomon, 2012, The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial, Lancet, 380, 1387, 10.1016/S0140-6736(12)61227-6 · DOI
  18. Verma, 2019, Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial, Circulation, 140, 1693, 10.1161/CIRCULATIONAHA.119.042375 · DOI
  19. Brown, 2020, A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial, Eur Heart J, 41, 3421, 10.1093/eurheartj/ehaa419 · DOI
  20. Sorimachi, 2022, Long-term changes in cardiac structure and function following bariatric surgery, J Am Coll Cardiol, 80, 1501, 10.1016/j.jacc.2022.08.738 · DOI
  21. Sargsyan, 2024, The effects of bariatric surgery on cardiac function: a systematic review and meta-analysis, Int J Obes (Lond), 48, 166, 10.1038/s41366-023-01412-3 · DOI
  22. Hughes, 2024, Impact of bariatric surgery on left ventricular structure and function, J Am Heart Assoc, 13
  23. Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, 28, 1, 10.1016/j.echo.2014.10.003 · DOI · Paper page
  24. Nagueh, 2016, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, 29, 277, 10.1016/j.echo.2016.01.011 · DOI · Paper page
  25. Melenovsky, 2015, Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction, Circ Heart Fail, 8, 295, 10.1161/CIRCHEARTFAILURE.114.001667 · DOI
  26. Reddy, 2019, Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis, JACC Heart Fail, 7, 678, 10.1016/j.jchf.2019.04.019 · DOI
  27. Obokata, 2022, Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity, Eur J Heart Fail, 24, 353, 10.1002/ejhf.2377 · DOI · Paper page
  28. McMurray, 2020, Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF, Circulation, 141, 338, 10.1161/CIRCULATIONAHA.119.044491 · DOI
  29. Sorimachi, 2022, Longitudinal evolution of cardiac dysfunction in heart failure and preserved ejection fraction with normal natriuretic peptide levels, Circulation, 146, 500, 10.1161/CIRCULATIONAHA.121.058592 · DOI
  30. Mohammed, 2014, Right ventricular function in heart failure with preserved ejection fraction: a community-based study, Circulation, 130, 2310, 10.1161/CIRCULATIONAHA.113.008461 · DOI
  31. Santos, 2016, Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction, Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.115.002763 · DOI
  32. Adamson, 2021, Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index, Eur J Heart Fail, 23, 1662, 10.1002/ejhf.2308 · DOI
  33. Butt, 2023, Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox, Eur Heart J, 44, 1136, 10.1093/eurheartj/ehad083 · DOI
  34. Carnicelli, 2021, Characteristics and outcomes of patients with heart failure with reduced ejection fraction after a recent worsening heart failure event, J Am Heart Assoc, 10
  35. Inciardi, 2022, Association of left atrial structure and function with heart failure in older adults, J Am Coll Cardiol, 79, 1549, 10.1016/j.jacc.2022.01.053 · DOI
  36. Lim, 2024, Change in left atrial function and volume predicts incident heart failure with preserved and reduced ejection fraction: Multi-Ethnic Study of Atherosclerosis, Eur Heart J Cardiovasc Imaging, 10.1093/ehjci/jeae138 · DOI
  37. Chung, 2020, Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association, Circulation, 141, e750, 10.1161/CIR.0000000000000748 · DOI
  38. Cikes, 2022, Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial, JACC Heart Fail, 10, 336, 10.1016/j.jchf.2022.01.018 · DOI
  39. Deanfield, 2024, Relevance of body weight and weight change on cardiovascular benefit with semaglutide: a pre-specified analysis of the SELECT trial, Obes Facts, 17, 491
  40. Cherney, 2021, Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, Med, 2, 1203, 10.1016/j.medj.2021.10.004 · DOI
  41. Ma, 2024, Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 Axis, Nat Comms, 15, 4757, 10.1038/s41467-024-48970-2 · DOI
  42. El Hajj, 2020, Echocardiography in the era of obesity, J Am Soc Echocardiogr, 33, 779, 10.1016/j.echo.2020.03.009 · DOI
  43. Snelder, 2019, Feasibility and reproducibility of transthoracic echocardiography in obese patients, J Am Soc Echocardiogr, 32, 1491, 10.1016/j.echo.2019.07.019 · DOI

Cited by

Sorted by citations

Metadata

Authors
Solomon, S. D., Ostrominski, J. W., Wang, X., Shah, S. J., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Verma, S., Abildstrøm, S. Z., Nygaard Einfeldt, M., Rasmussen, S., Abhayaratna, W. P., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ito, H., Merkely, B., Núñez, J., Senni, M., van der Meer, P., Wolf, D., Petrie, M. C., & Kosiborod, M. N.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2024-10
Volume
84
Issue
17
Pages
1587-1602
ISSN
0735-1097
DOI
10.1016/j.jacc.2024.08.021
Cited by
154
References
11
Language
en
Update notices
erratum (2025-03-11)
Licence
Funders
Novo Nordisk (GPP 2023)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review